Article
Molecular mechanism of resistance to lonafarnib conferred by mutations in the cysteine-rich region of respiratory syncytial virus fusion glycoprotein and discovery of a lonafarnib-derived antiviral PROTAC.
Journal of virology - 20 Jan 2026
Yang Qi, Xue Bao, Qiu Xianjie, Yang Kaixin, Tang Jielin, Zhou Anqi, Zou Jingjing, Mao Yuhan, Zhong Jiayi, Zhou Yuan, Zhang Wei, Zhang Qiong, Xiao Qingyu, Tang Wei, Li Zhiyu, Ye Wencai, Zou Gang, Peng Wei, Shang Jinsai, Xu Xi, Li Yixue, Chen Xinwen
Abstract excerpt
Lonafarnib, an oral antiviral that targets the fusion glycoprotein of respiratory syncytial virus (RSV), has demonstrated efficacy in vitro and in vivo. However, because the RSV has evolved to become resistant to other fusion inhibitors, there is a concern that the same could occur for lonafarnib. Here, we identified resistance to lonafarnib in the RSV A2 strain and a recent clinical isolate, RSV ON1, via in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.